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Abstract: Chronic kidney disease (CKD) is a global health problem associated with a number of 
comorbidities. Recent evidence implicates increased hemichannel-mediated release of adenosine 
triphosphate (ATP) in the progression of tubulointerstitial fibrosis, the main underlying pathology 
of CKD. Here, we evaluate the effect of danegaptide on blocking hemichannel-mediated changes in 
the expression and function of proteins associated with disease progression in tubular epithelial 
kidney cells. Primary human proximal tubule epithelial cells (hPTECs) were treated with the beta1 
isoform of the pro-fibrotic cytokine transforming growth factor (TGFβ1) ± danegaptide. qRT-PCR 
and immunoblotting confirmed mRNA and protein expression, whilst a cytokine antibody array 
assessed the expression/secretion of proinflammatory and profibrotic cytokines. Carboxyfluores-
cein dye uptake and ATP biosensing measured hemichannel activity and ATP release, whilst tran-
sepithelial electrical resistance was used to assess paracellular permeability. Danegaptide negated 
carboxyfluorescein dye uptake and ATP release and protected against protein changes associated 
with tubular injury. Blocking Cx43-mediated ATP release was paralleled by partial restoration of 
the expression of cell cycle inhibitors, adherens and tight junction proteins and decreased paracel-
lular permeability. Furthermore, danegaptide inhibited TGFβ1-induced changes in the expression 
and secretion of key adipokines, cytokines, chemokines, growth factors and interleukins. The data 
suggest that as a gap junction modulator and hemichannel blocker, danegaptide has potential in the 
future treatment of CKD. 
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1. Introduction 
Chronic kidney disease (CKD) is a growing health concern associated with increased 
risk of cardiovascular disease and morbidity [1]. Estimated to affect 10% of the global 
population [2], risk factors include age, diabetes, hypertension, dyslipidaemia and obesity 
[3]. The disease is characterised by a decline in the glomerular filtration rate (GFR), in 
addition to proteinuria, with glomerulosclerosis, tubular atrophy and tubulointerstitial 
fibrosis (TIF), which are common histopathological changes [4]. Culminating in the loss 
of epithelial stability, persistent inflammation and increased deposition of the extracellu-
lar matrix [5,6], treatment of TIF and advanced CKD represents an unmet clinical need 
[3]. Consequently, urgent therapeutic approaches are required. 
Altered connexin (Cx) expression and function have been implicated in the pathol-
ogy of various forms of disease (as reviewed in [7]), including CKD (as reviewed in [8,9]). 
Connexins are a family of membrane-bound proteins that oligomerise into hexameric as-
semblies termed connexons [10]. When neighbouring cells align, connexons dock to form 
gap junctions, continuous pores through which messenger molecules can be exchanged, 
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allowing a direct route of communication [10]. When unbound, connexons form hemi-
channels through which molecules, e.g., adenosine triphosphate (ATP), can be released 
into the local extracellular space to influence neighbouring cells via activation of puri-
noreceptors [11]. Expression of the purinergic P2X7 receptor (P2X7R) is upregulated in the 
renal tubules of individuals with diabetic kidney disease [12] and has been heavily impli-
cated in the progression of fibrosis both in the kidney [13–17] and in other tissue types 
[18–21]. Unsurprisingly, targeting purinergic signalling has received considerable atten-
tion. However, to date, clinical trials have failed to demonstrate beneficial effects of P2X7R 
antagonism in numerous inflammatory conditions, an effect perhaps associated with ge-
netic variation within the receptor [22]. Targeting upstream of ATP release would circum-
vent these problems. 
Evidence links the aberrant expression and/or activity of connexins with various 
forms of CKD [12,23–26]. Initial studies by Abed et al. reported that heterogenous (Cx43+/−) 
mice, with unilateral ureteral obstruction (UUO), exhibited reduced extracellular matrix 
(ECM) deposition and decreased inflammation [27], whilst the Cx43-specific mimetic, 
GAP-26, was able to inhibit monocyte adhesion and blunted the expression of collagen I 
in the renin transgene (RenTG) mouse model of renin-dependent CKD [25]. More recently, 
we identified that the predominant connexin isoform expressed in the proximal tubule, 
Cx43, is elevated in biopsy material isolated from individuals with diabetic nephropathy, 
an observation paralleled by increased hemichannel-mediated ATP release in TGFβ1-
treated primary proximal tubule cells [12]. In evaluating the impact of local increases in 
extracellular ATP concentrations, we determined that aberrant Cx43-mediated communi-
cation initiates disassembly of adherens (e.g., E-cadherin) and tight (e.g., Zona Occludens) 
junction complexes via activation of P2X7R. These effects, which were negated in a heter-
ogeneous Cx43+/− mouse model of UUO [12], suggest a clear link between Cx43 and tubu-
lar injury. Whilst partial ablation of Cx43 confirms a role for connexins in initiating phe-
notypic changes of tubular injury, pharmacological intervention with the Cx43 hemichan-
nel blocker peptide5 established that the protective nature of this diminished Cx43 activity 
stems from inhibition of hemichannel-mediated ATP release. The use of mimetic peptides 
to underscore the protective nature behind blocking hemichannel activity has been suc-
cessfully reported in other models of disease, including retinopathy [28], neuroinflamma-
tion [29], glioma [30,31] and age-related macular degeneration [32,33]. Ultimately, studies 
link altered connexin activity to increased inflammation [34–36] and fibrosis [37–40] and 
suggest that stabilising hemichannel- and/or gap-junction-mediated communication 
(GJIC) may delay the onset of damage observed in various models of injury. Conse-
quently, inhibiting connexin hemichannels provides an attractive means to reduce inflam-
mation and is of considerable therapeutic interest. 
Danegaptide ((2S, 4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine2-carboxylic acid), 
also known as ZP1609 or GAP-134, is a small dipeptide derived from rotigaptide (AAP10, 
ZP123). Originally developed as an anti-arrhythmic agent [41], it interacts with Cx43 [42] 
and acts as a potent gap junction modifier [43]. The compound has demonstrated protective 
and anti-arrhythmic properties and has previously shown significant effects in established 
preclinical models of cardiac ischemic reperfusion injuries [44,45]. Whilst phase 2 human 
clinical trials unfortunately failed to meet their end point [46], studies from other groups 
have explored the therapeutic potential of danegaptide in other tissue types and models of 
disease [41,47–49]. Moreover, whilst little is known of its role in modulating hemichannel 
activity, it has been demonstrated that danegaptide reduces hemichannel-mediated dye up-
take in C6 glioma cells [43]. Despite this, a role for this compound in blocking hemichannel-
mediated ATP release in other tissue types remains to be confirmed. 
The current study investigated the efficacy of danegaptide in negating connexin-medi-
ated hemichannel ATP release in primary TGFβ1-treated human proximal tubule epithelial 
cells (hPTECs), ahead of delineating its protective role against the expression and functional 
changes commonly associated with progression of tubulointerstitial fibrosis. Using tech-
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niques to determine changes in expression (qRT-PCR, immunocytochemistry, immunoblot-
ting, antibody arrays) and function (ATP biosensing, dye uptake, transepithelial electrical 
resistance, antibody arrays), our findings demonstrate that nanomolar concentrations of 
danegaptide block Cx hemichannel-mediated ATP release and partly attenuate TGFβ1-in-
duced changes in the expression of cell cycle proteins (e.g., p16, p21, cyclin D1) and reno-
protective factors (e.g., Klotho). Moreover, danegaptide decreases the changes often ob-
served in tubular injury, including disassembly of adherens junctions (including a loss of E-
cadherin) and tight junctions (including a loss of zona occludens 1 (ZO-1) and claudin 2). 
Importantly, the proteome profiler array demonstrated the ability of danegaptide to restore 
changes in the expression and secretion of key extracellular matrix proteins, adipokines, 
chemokines and growth factors induced by TGFβ1. Consequently, our in vitro data suggest 
that danegaptide (50–100 nM) can successfully block hemichannel-mediated ATP release in 
primary hPTECs and partially protect against changes associated with inflammation and 
fibrosis, as observed in late-stage CKD. 
2. Results 
2.1. Danegaptide Does Not Affect Tubular Epithelial Cell Viability 
Human kidney 2 (HK2) cells were cultured in low glucose (5 mM) for 48 h, prior to 
being serum-starved overnight and subsequently treated with the optimum concentration 
of TGFβ1 (10 ng/mL) [12,24] ± danegaptide (50 nM–1 μM) for 48 h (Figure 1A, n = 3). A 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay confirmed that 
neither TGFβ1 (101.9 ± 11.7%) nor danegaptide alone altered cell viability (95.2 ± 7% (50 nM), 
103 ± 5.7% (100 nM) and 96.6 ± 5.3% (1 μM)) as compared to controls. No effect was observed 
when TGFβ1-treated cells were co-incubated with danegaptide (104.1 ± 2.2% (50 nM), 93.4 
± 1.6% (100 nM) and 89.3 ± 3.7% (1 μM)). To corroborate these data, a crystal violet (CV) and 
lactate dehydrogenase (LDH) assay was performed. LDH release in TGFβ1-treated cells 
was comparable to controls (109.3 ± 11.3%), and co-incubation with danegaptide had no 
additional effect (106.4 ± 11.6% (50 nM), 113.9 ± 15.6% (100 nM) and 113.2 ± 4.3% (1 μM)). As 
expected, danegaptide alone did not significantly alter LDH release compared to controls 
(104.4 ± 4.3% (50 nM), 95.3 ± 4.7% (100 nM) and 92.6 ± 3.3% (1 μM)). Cell staining using 
crystal violet recapitulated these findings, with data for TGFβ1 (10 ng/mL; 96.9 ± 7.3%) and 
TGFβ1 plus danegaptide (50 nM–1 μM) being comparable to controls (98.2 ± 1.9% (50 nM), 
97.5 ± 1.8% (100 nM) and 85.8 ± 5.3% (1 μM). Lastly, danegaptide alone did not alter crystal 
violet staining (98.3 ± 2.5% (50 nM), 99.6 ± 2.7% (100 nM) and 98.5 ± 2.2% (1 μM) of controls). 
In light of these data, a concentration of 50–100 nM was selected for subsequent studies. 




Figure 1. Danegaptide prevents TGFβ1-evoked increases in hemichannel-mediated dye uptake. In 
panel (A), human kidney 2 (HK2) cells were cultured in low glucose (5 mM) ± TGFβ1 (10 ng/mL) ± 
danegaptide (50, 100 and 1000 nM) for 48 h and cell viability assessed. Results are presented as the 
mean ± SEM (n = 3). Incubation with TGFβ1 (10 ng/mL ± danegaptide (50–1000 nM)) did not alter 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) uptake, lactate dehydrogenase 
(LDH) release or crystal violet (CV) staining. In panels (B) and (C), carboxyfluorescein dye uptake 
was used to assess hemichannel activity in HK2 cells and human proximal tubule epithelial cells 
(hPTECs), with the degree of dye loading being directly proportional to opening. Cells were cul-
tured in low glucose (5 mM) ± TGFβ1 (10 ng/mL) ± danegaptide (50 or 100 nM) for 48 h. Danegaptide 
prevented TGFβ1-evoked increases in carboxyfluorescein dye uptake in HK2 cells (panel (B)) and 
hPTECs (panel (C)). Minimal dye loading occurred in control cells, whilst dye loading significantly 
increased in cells treated with TGFβ1. Addition of danegaptide (50 or 100 nM) reduced dye uptake, 
returning the fluorescence intensity to control levels. Intensity is expressed as a percentage com-
pared to low-glucose controls and is representative of 3 separate experiments. Data are presented 
as the mean ± SEM (n = 3), with key significances indicated (** p < 0.01, *** p < 0.001; one-way ANOVA 
and Tukey’s post-test). 
Int. J. Mol. Sci. 2021, 22, 2809 5 of 21 
 
 
2.2. Danegaptide Blocks TGFβ1-Evoked Changes in Hemichannel-Mediated Dye Uptake in Tub-
ular Epithelial Cells 
We have previously shown that TGFβ1 increases Cx43-mediated hemichannel activ-
ity and ATP release from proximal tubule epithelial cells [24]. A carboxyfluorescein dye 
uptake assay was used to determine whether danegaptide can negate TGFβ1-induced dye 
uptake through hemichannels in HK2 cells and primary hPTECs. As expected, TGFβ1 (10 
ng/mL) increased dye uptake to 354.9 ± 32.6% of controls in HK2 cells, whilst co-incuba-
tion with danegaptide (50 nM and 100 nM) significantly blunted the response to 165.5 ± 
17.9% and 147.6 ± 18.1%, respectively (Figure 1B; p ≤ 0.001, n = 4). Danegaptide alone did 
not alter dye uptake. Carboxyfluorescein dye uptake was increased by TGFβ1 (10 ng/mL) 
in primary hPTECs (310.8 ± 38.6% of controls), a response partly negated by the co-incu-
bation of danegaptide (100 nM; 145 ± 19.7%) as compared to controls (Figure 1C; p ≤ 0.01, 
n = 4). 
2.3. Danegaptide Negates TGFβ1-Induced Hemichannel-Mediated ATP Release in HK2 Cells 
To determine whether danegaptide (50–100 nM) could prevent TGFβ1 (10 ng/mL)-
induced release of ATP from hemichannels in HK2 cells, we used ATP biosensing [24,50]. 
TGFβ1 (10 ng/mL) increased ATP release from 0.33 ± 0.11 μM to 3.60 ± 0.29 μM (Figure 
2A,B,E; p ≤ 0.001), an effect partially negated by danegaptide at both 50 nM (1.90 ± 0.26 
μM; p ≤ 0.01) and 100 nM (0.79 ± 0.19 μM; p ≤ 0.001) (Figure 2D,E, n = 3, six repeats/sample 
number). Danegaptide alone did not affect ATP release (Figure 2C and E), with ATP levels 
recorded at 0.35 ± 0.10 μM (50 nM) and 0.31 ± 0.09 μM (100 nM) as compared to controls 
(Figure 2E). 
 
Figure 2. Danegaptide prevents TGFβ1-evoked increases in ATP release. HK2 cells were cultured 
in low glucose (5 mM) with/without TGFβ1 (10 ng/mL) ± danegaptide (50 or 100 nM) for 48 h. Rep-
resentative biosensor traces show ATP release following removal of extracellular calcium. Control 
cells (panel (A)) exhibit negligible ATP release compared to a calibration (CALIB) response to 10 
μM ATP, whilst a marked increase in release was observed from TGFβ1-treated cells (panel (B)). 
Danegaptide (100 nM) alone failed to alter basal ATP (panel (C)) but significantly reduced TGFβ1-
evoked ATP release (panel (D)). Peak responses were quantified by comparing against a known 
concentration of ATP (10 μM) and mean data ± SEM plotted (panel (E)). Results are representative 
of 3 separate experiments (n = 3; ** p < 0.01, *** p < 0.001; one-way ANOVA and Tukey’s post-test). 
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2.4. Danegaptide Reverses TGFβ1-Induced Changes in Cell Cycle Proteins and a Marker of 
Reno-Protection in hPTECs 
To determine whether danegaptide can negate hemichannel-mediated regulation of 
common cell cycle and reno-protective markers, hPTECs were incubated with TGFβ1 (10 
ng/mL) ± danegaptide (100 nM) for 12 h and the expression of candidate gene mRNA 
assessed through qPCR analysis. Addition of danegaptide to TGFβ1-treated hPTECs re-
turned the expression of p16 from 358.8 ± 21.1% to 193 ± 18.5% of controls, p21 expression 
from 221.8 ± 12.9% to 142.2 ± 6.2% and cyclin D1 expression from 253.2 ± 7.7% to 132.9 ± 
15.0% (Figure 3; p ≤ 0.001, n = 3). In addition, danegaptide partially reversed the decline in 
Klotho from 43.3 ± 3.8% to 59.9 ± 11.7% of controls (Figure 3, n = 3). 
 
Figure 3. Danegaptide reduces TGFβ1-induced mRNA changes in cell cycle and reno-protective 
markers. Primary hPTECs were cultured in low glucose (5 mM) ± TGFβ1 (10 ng/mL) ± danegaptide 
(100 nM) for 12 h. In TGFβ1-treated cells, qPCR analysis demonstrated an increase in p16, p21 and 
cyclin D1 mRNA and a significant reduction in Klotho mRNA as compared to controls. Danegaptide 
(100 nM) partly negated the increase in p16, p21 and cyclin D1 and reversed the TGFβ1-evoked 
change in Klotho. Results are representative of 3 separate experiments and presented as the mean ± 
SEM (n = 3), with key significances indicated (** p < 0.01, *** p < 0.001; one-way ANOVA and Tukey’s 
post-test). 
2.5. Danegaptide Restores TGFβ1-Mediated Changes in Adherens and Tight Junction Proteins 
and Paracellular Permeability in hPTECs 
In the kidney, reduced E-cadherin (ECAD)-mediated cell adhesion initiates a series 
of events that culminate in an intermittent phenotype associated with partial epithelial-
to-mesenchymal transformation. Initiation facilitates disassembly of both adherens and 
tight junction complexes, culminating in loss of adhesion, diminished gap junction inter-
cellular communication and leaky epithelia [12,24,51]. To determine whether danegaptide 
can negate TGFβ1-mediated changes in adherens and tight junction proteins, hPTECs 
were incubated with TGFβ1 (10 ng/mL) ± danegaptide (100 nM) for 48 h and expression 
of candidate proteins assessed. Danegaptide partially restored E-cadherin expression 
from 33.3 ± 3.3% to 89 ± 7.6% of controls, N-cadherin (NCAD) expression from 224.4 ± 29.6 
to 161.9 ± 27.4% and vimentin expression from 212.9 ± 13% to 147.3 ± 8.8% (Figure 4A; p ≤ 
0.001, p ≤ 0.01 and p ≤ 0.001, respectively; n = 3). β-catenin expression remained unaltered 
by the hemichannel blocker from 149.2 ± 11.2% (TGFβ1 alone) to 151.6 ± 16.8% (TGFβ1 + 
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danegaptide, Figure 4B; p = NS, n = 3). Assessment of the effects of danegaptide on tight 
junction proteins confirmed that the gap junction modulator partially restored the expres-
sion of claudin-2 from 44.5 ± 5% to 74.6 ± 5% of controls and ZO-1 from 27.8 ± 11.3% to 
52.8 ± 5.4% as compared to controls (Figure 4B; p ≤ 0.05, n = 3). Studies examining transep-
ithelial electrical resistance confirmed that reduced expression of tight junction proteins 
seen with TGFβ1 (10 ng/mL) is paralleled by a loss of transepithelial resistance from 57.33 
± 1.86 Ω.cm2 to 10 ± 1.53 Ω.cm2 (p ≤ 0.001, n = 3). This increased leakiness was partially 
corrected by co-incubation with danegaptide (36 ± 2.08 Ω.cm2) (Figure 4C; p ≤ 0.001, n = 3). 
 
Figure 4. Danegaptide reduces TGFβ1-evoked changes in adherens and tight junction proteins and 
epithelial leakiness. Primary hPTECs were cultured in low glucose (5 mM) ± TGFβ1 (10 ng/mL) ± 
danegaptide (100 nM) for 48 h. Expression of E-cadherin (ECAD), N-cadherin (NCAD) and vimentin 
(panel (A)) and of claudin-2, zona occludens 1 (ZO-1) and β-catenin (panel (B)) was assessed via 
Western blotting. TGFβ1 reduced E-cadherin, claudin-2 and ZO-1 expression and increased N-cad-
herin and vimentin expression. Effects were partially reversed by danegaptide (100 nM). Repre-
sentative blots for each protein are shown, with expression normalised by re-probing for ɑ-tubulin 
as a loading control. Results are presented as the mean ± SEM (n = 3), with key significances indi-
cated (* p < 0.05, ** p < 0.01, *** p < 0.001; one-way ANOVA and Tukey’s post-test). In panel (C), 
transepithelial electrical resistance (TER) assessed the consequence of altered adherens and tight 
junction protein expression on epithelial integrity. HK2 cells were cultured in low glucose (5 mM) 
on Transwell inserts and transepithelial resistance measured. TGFβ1 reduced TER, an effect partially 
restored by the addition of danegaptide (100 nM). Data are expressed as the mean ± SEM (n = 3; *** 
p < 0.001). 
2.6. Danegaptide Prevents TGFβ1-Evoked Upregulation of Extracellular Matrix Proteins in 
hPTECs 
Caused by an imbalance between formation and degradation, the accumulation of 
the ECM is a major hallmark of CKD. A role for TGFβ1 in this process is well established 
[52], and understanding how to negate these changes has clear implications to progression 
of the disease. To examine the effect of danegaptide on TGFβ1-evoked changes in the ex-
pression of ECM proteins, hPTECs were cultured in low glucose (5 mM) for 48 h, serum-
starved overnight and treated with TGFβ1 (10 ng/mL) ± danegaptide (100 nM) for 48 h. 
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Compared to controls, TGFβ1 increased the expression of the ECM proteins collagen I 
(334.6 ± 30.14%), collagen IV (354.5 ± 16.9%), fibronectin (301.7 ± 50.4%) and laminin (324.8 
± 36.4%) (Figure 5A,B; p ≤ 0.001, n = 3). Co-incubation with danegaptide significantly at-
tenuated these changes, restoring the expression to 180.7 ± 27.3% (collagen I), 164 ± 6.9% 
(collagen IV), 161.3 ± 4% (fibronectin) and 149 ± 20.4% (laminin) (p ≤ 0.001; n = 3 in each 
case). Danegaptide (100 nM) also reduced TGFβ1 (10 ng/mL)-evoked changes in integrin-
linked kinase 1 (ILK1) from 378.9 ± 16.8% to 251.8 ± 33% (p ≤ 0.001) but had minimal effect 
on matrix metalloproteinase 3 (MMP3), reducing the expression from 185.3 ± 19.6% with 
the cytokine alone to 147.1 ± 12.2% when co-incubated with danegaptide (Figure 5B). 
 
Figure 5. Danegaptide negates TGFβ1-evoked changes in the expression of proteins associated with 
the extracellular matrix. Primary hPTECs were cultured in low glucose (5 mM) ± TGFβ1 (10 ng/mL) ± 
danegaptide (100 nM) for 48 h. In panel (A), expression of collagen I (Col1), collagen IV (Col4), fibron-
ectin (Fibro) and laminin (panel (B)) was assessed via Western blotting. TGFβ1 upregulated extracel-
lular matrix (ECM) protein expression, an effect reduced by danegaptide (100 nM). Similarly, 
danegaptide partially reversed TGFβ1-evoked changes in matrix metalloproteinase 3 (MMP3) and in-
tegrin-linked kinase 1 (ILK1). Representative blots are shown, with expression normalised by re-prob-
ing for ɑ-tubulin as a loading control. Bars correspond to their associated lanes in the respective blot. 
Results are presented as the mean ± SEM (n = 3; * p < 0.05, *** p < 0.001; one-way ANOVA and Tukey’s 
post-test). 
2.7. Danegaptide Reduces TGFβ1-Evoked Changes in the Expression of Adipokines, Chemokines, 
Growth Factors and Interleukins from hPTECs 
The inflammatory response in and around proximal tubules involves both the activa-
tion of multiple cell types and the secretion of numerous inflammatory markers. Specifi-
cally, soluble chemokines, cytokines and growth factors recruit and activate infiltrating im-
mune cells and stimulate resident fibroblasts. Sustained activation of these cells mediates 
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tubulointerstitial fibrosis. We used the proteome profiler array to determine whether 
danegaptide negates TGFβ1-induced changes in the expression and secretion of key proin-
flammatory mediators. Primary hPTECs were cultured, as described above, and treated 
with TGFβ1 (10 ng/mL) ± danegaptide (100 nM) for 48 h. A list of changes in lysate (Figure 
6) and supernatant (Figure 7) are provided for 31 candidate proteins grouped by primary 
function. 
 
Figure 6. Danegaptide prevents TGFβ1-evoked changes in the expression of adipokines, chemo-
kines, growth factors and interleukins. Primary hPTECs were cultured in low glucose (5 mM) ± 
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TGFβ1 (10 ng/mL) ± danegaptide (100 nM) for 48 h. An inflammation antibody array was used to 
assess the expression of 31 candidate inflammatory proteins in hPTEC lysates. Results are repre-
sentative of 3 separate experiments and presented as the mean ± SEM (n = 3), with key significances 
indicated (* p < 0.05, ** p < 0.01, *** p < 0.001; one-way ANOVA and Tukey’s post-test). 
 
Figure 7. Danegaptide prevents TGFβ1-evoked changes in the secretion of adipokines, chemokines, 
growth factors and interleukins. Primary hPTECs were cultured in low glucose (5 mM) ± TGFβ1 (10 
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ng/mL) ± danegaptide (100 nM) for 48 h. An inflammation antibody array was used to assess the 
secretion of 31 candidate inflammatory proteins in the supernatant from treated hPTECs. Results 
are representative of 3 separate experiments and presented as the mean ± SEM (n = 3), with key 
significances indicated (* p < 0.05, ** p < 0.01, *** p < 0.001; one-way ANOVA and Tukey’s post-test). 
3. Discussion 
In 2017, the global incidence of CKD was at 697.5 million cases, with the condition 
identified as the 12th-leading cause of death worldwide [53]. To date, there are no curative 
therapeutic options for end-stage renal disease (ESRD). Furthermore, with low dialysis 
survival rates and a global shortage of kidney donors, there is a pressing need to develop 
therapies that could prevent CKD progression and improve the patient’s quality of life. 
In CKD, the severity of inflammation in the proximal tubule dictates how quickly a 
kidney will fail. Contributed to by the activation of multiple cell types, it appears, in part, 
to involve connexin-mediated cell-to-cell communication [9]. Connexins facilitate direct 
and local paracrine-mediated cell communication through their ability to oligomerise into 
hexameric connexons. When neighbouring cells align, connexons dock to form gap junc-
tions [10]. These continuous channels provide a direct route for information transfer, al-
lowing cells to lock into a particular frequency and synchronise activity. In contrast to gap 
junctions, which typically open under physiological conditions, undocked connexons, 
also termed hemichannels, have a low open probability and open in response to injury 
[10]. Altered hemichannel activity is associated with the pathophysiology of multiple dis-
ease states, with evidence linking altered cell-to-cell communication to increased senes-
cence [54], inflammation [34,55,56] and fibrosis [18–21]. Data from our own lab demon-
strate that the predominant connexin isoform in the proximal tubule (Cx43) is up-regu-
lated in advanced CKD and correlates with elevated levels of TGFβ1 and severity of fibro-
sis and inflammation [24]. Moreover, this altered expression translates to a loss of gap 
junction intercellular communication, which is accompanied by increased hemichannel-
mediated ATP release and changes indicative of early tubular injury. Consequently, 
blocking Cx43-mediated hemichannel ATP release may represent a viable target for treat-
ment of the late-stage damage that develops in individuals with CKD. 
Danegaptide is a small therapeutic peptide that until recently has been used in its 
capacity to restore gap junction coupling in multiple models of injury, including ischae-
mia [43,44] and retinopathy [49]. Danegaptide has been shown to block hemichannel ac-
tivity and dye uptake in C6 glioma cells [43]; however, a role for the compound in blocking 
hemichannel-mediated ATP release remains to be confirmed, and no studies have yet 
evaluated the effects of danegaptide on injured kidney tubules. In the current study, we 
presented compelling evidence that danegaptide blocks TGFβ1-induced hemichannel-
mediated ATP release in primary human proximal tubule epithelial cells. Furthermore, 
the compound restored TGFβ1-evoked changes in the expression and secretion of proteins 
linked to inflammation and fibrosis. In CKD, tubulointerstitial fibrosis develops in re-
sponse to various morphological and phenotypic changes, including epithelial-to-mesen-
chymal transition (EMT), inflammatory cell infiltration, fibroblast activation and extracel-
lular matrix (ECM) remodelling [57]. Recent evidence suggests that cellular senescence 
may play a key role in the progression of chronic kidney disease [58], with senescence 
linked to EMT, a proinflammatory secretome, and extracellular matrix deposition [59–62]. 
Senescence denotes irreversible proliferative growth arrest with associated changes in 
chromatin organisation, gene transcription and protein secretion [63,64]. Consequently, 
senescent cells are known to exhibit increased expression of cyclin-dependent kinase 
(CDK) inhibitors (CKIs), including p21Cip1 (p21) and p16Ink4a (p16), and altered expression 
of reno-protective Klotho [65–68]. In the current study, mRNA expression of CDK inhibi-
tors p16, p21 and cyclin D1 was significantly elevated in TGFβ1-treated tubular epithelial 
cells, whilst the reno-protective anti-aging protein Klotho demonstrated reduced expres-
sion compared to controls. Interestingly, the expression of p16, p21 and cyclin D1 was 
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ameliorated when cells were co-incubated with danegaptide. The importance of this ob-
servation is supported by numerous in vivo studies [69,70], including recent work in the 
p16 INK4a double-knockout mouse model. When induced with UUO to exhibit advanced 
interstitial inflammation and fibrosis, these mice exhibited decreased apoptosis, senes-
cence, diminished levels of TGFβ1/Smad signalling and a reduction in inflammatory cell 
infiltration as compared to wild-type animals [70]. Moreover, proximal tubule cells iso-
lated from the UUO model exhibited increased levels of p21, suppression of which is par-
alleled by a reduction in markers commonly associated with EMT [71,72]. A direct link to 
cell senescence and induction of EMT has already been established [73]. 
The loss of E-cadherin-mediated cell adhesion is an initiating trigger of EMT, with a 
concomitant increase in N-cadherin (the cadherin switch), accompanied by disassembly 
of the adherens junction and acquisition of proteins commonly associated with a fibroblast 
phenotype, e.g., vimentin and fibroblast-specific protein [74]. In the kidney, it is well es-
tablished that tubular injury evokes a number of morphological and phenotypic changes 
characteristic of partial, if not full, EMT. Our recent studies demonstrated that glucose-
evoked changes in TGFβ1 mediate disassembly of the adherens and tight junction com-
plex by regulating changes in adherens (ECAD, NCAD, β-catenin) and tight junction (ZO-
1) protein expression. Moreover, in vitro administration of non-hydrolysable ATP down-
regulated E-cadherin expression in proximal kidney cells, the loss of which was paralleled 
by a reduction in intercellular ligation forces, decreased tether rupture events and cyto-
skeletal remodelling [51]. Mediated by P2X7R, the effects were reversed in the hetero-
genous Cx43+/- UUO model [12]. Building on these findings, the effectiveness of 
danegaptide underscores a protective role for blocking hemichannel-mediated ATP re-
lease in preventing altered expression of key epithelial (ECAD, β-catenin, ZO-1, claudin 
2) and mesenchymal (NCAD, vimentin) proteins, the implications of which are of thera-
peutic interest. 
The adherens junction assembles when the cytoplasmic tail of E-cadherin binds to β-
catenin, mediating attachment to the cytoskeletal network and ensuring that cell polarity 
and architecture are maintained [75]. Despite its role in maintaining cell polarity, disas-
sembly of these junctions allows for the release of β-catenin into the cytosol, which when 
activated by either Wnt proteins or other upstream regulators, e.g., integrin-linked kinase 
(ILK), can translocate into the nucleus and regulate cell-specific effects. Integrin-linked 
kinase is an intracellular serine/threonine protein kinase that plays a fundamental role in 
the regulation of cell adhesion, survival, proliferation and extracellular matrix (ECM) dep-
osition [76]. Importantly, inhibition of ILK attenuates renal fibrosis in multiple models of 
CKD [77]. In the current study, TGFβ1-induced increases in ILK1 expression were, in part, 
restored when cells were co-incubated with danegaptide, an effect that paralleled a de-
crease in β-catenin expression and ECM-related proteins. Interestingly, whilst 
danegaptide failed to significantly alter the TGFβ1-induced increase in β-catenin expres-
sion, it is important to note that the absence of a change in expression does not reflect the 
absence of its function within the cell. The canonical Wnt pathway involves the nuclear 
translocation of β-catenin and activation of target genes via a group of transcription fac-
tors called the T cell factor/lymphoid enhancer factors (TCF/LEF) [78]. Normally, Wnt/β-
catenin signalling is silent, but it is reactivated after injury in a number of different models 
of chronic kidney disease [79,80]. Moreover, aberrant Wnt/β-catenin signalling is highly 
associated with the initiation of senescence, an effect that parallels the loss of expression 
of Klotho, an anti-aging protein that acts as a negative regulator of the canonical Wnt 
pathway [81], and in the current study was downregulated in TGFβ1-treated cells (Figure 
3). Consequently, sustained activation of Wnt/β-catenin signalling is linked to the pro-
gression of fibrosis in both the kidney and other tissue types [79,82,83]. Once translocated 
into the nucleus, β-catenin is associated with increased expression of the transcription fac-
tor SNAIL and the matrix metalloproteinase MMP7. Interestingly, these events are asso-
ciated with transcriptional repression and extracellular domain membrane shedding of E-
cadherin, the latter of which sees an increase in the cytoplasmic pool of free β-catenin [84]. 
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Accordingly, Wnt signalling is a key activator of EMT in conditions of injury [85]. More-
over, with evidence that Wnt/β-catenin signalling promotes the expression of numerous 
genes, including fibronectin, FSP1, Snail1, MMP7 and cyclin D1, it is not surprising that 
attenuation of this signalling cascade is associated with improved renal function, reduced 
EMT [86] and diminished inflammation [87] and fibrosis [80,88]. Consequently, it could, 
in part, account for the TGFβ1-induced increased expression and secretion of extracellular 
matrix proteins (Figure 5), proinflammatory cytokines and chemokines observed in this 
study (Figures 6 and 7). Increased ECM deposition and secretion of proinflammatory mol-
ecules are hallmarks of tubulointerstitial fibrosis, with different cell types, including renal 
tubular epithelial cells known to secrete a large number of factors that are collectively 
defined as the CKD-associated secretory phenotype (CASP). Characterised by numerous 
molecules, including interleukins, extracellular matrix proteins and chemokines, this 
CASP bares striking similarities to the senescence-associated secretory phenotype (SASP), 
with components of the CASP having been strongly associated with the pathology of tu-
bulointerstitial fibrosis [89]. When released, these proinflammatory factors act upon 
neighbouring healthy cells in a paracrine fashion, thereby driving the progression of fi-
brosis in CKD. As many factors associated with the CASP are known to induce fibrosis in 
the kidney (e.g., TGFβ, interleukin (IL)-1, and interleukin (IL)-6), targeting upstream of 
these inflammatory signalling intermediates might prove an effective alternative strategy 
for CKD treatment. Using a proteome profile array, the cell supernatant from 
TGFβ1±danegaptide-treated cells was incubated on a cell membrane preabsorbed with 
antibodies raised against key inflammatory proteins. As highlighted in Figures 6 and 7, 
co-incubation of cells with TGFβ1 and danegaptide restored the expression and secretion 
of a number of candidate proteins whose role in kidney disease is well established as ei-
ther detrimental (tumour necrosis factor-alpha, interleukin 1-alpha, interferon-gamma) or 
protective (hepatocyte growth factor). Moreover, in CKD, soluble chemokines, adhesion 
molecules and growth factors recruit and activate infiltrating immune cells and resident 
fibroblasts to mediate inflammation and fibrosis in the injured kidney. Our array data 
confirm that modulating Cx43 and blocking hemichannel-mediated ATP release in tubu-
lar epithelial cells negates, either in part or fully, secretion of many inflammatory media-
tors, including chemokines, monocyte chemo-attractant protein (MCP1) and Regulated 
on Activation, Normal T Cell Expressed and Secreted (RANTES), both of which are in-
volved in monocyte recruitment. Elevated in both human and experimental kidney dis-
eases, MCP1 secretion is triggered by interleukin-1, tumour necrosis factor-alpha [90] and 
interferon-gamma [91], all of which were induced in our model by TGFβ1, yet blocked 
when co-applied with danegaptide. Moreover, danegaptide was also observed to prevent 
TGFβ1-induced secretion of intercellular cell adhesion molecule (ICAM1) [92], granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) [93] and epithelial-neutrophil-acti-
vating peptide (ENA78) [94]. Collectively, these have been linked to the progression of 
CKD and with other key pathogenic proteins, including dipeptidyl peptidase 4 (DPPIV) 
[95] and vascular endothelial growth factor (VEGF) [96], and have been identified as po-
tential therapeutic targets. Despite these observations, array analysis identified a number 
of proteins at 48 h, where TGFβ1-induced regulation appeared to independent of hemi-
channel-mediated ATP release. As evidenced by the expression of the FLT3 ligand in the 
cell lysate, danegaptide failed to significantly alter TGFβ1-induced changes in whole-cell 
expression. The FLT3 ligand is initially synthesised as a membrane-bound protein, which 
must be cleaved to become a soluble growth factor. In TGFβ1-treated cells, an increase in 
membrane-bound FLT3L was observed compared to controls in the cell lysate, a response 
that was unaffected when cells were co-incubated with danegaptide. Although little is 
known about the enzyme involved in the proteolytic cleavage and release of FLT3L, a 
study by Horiuchi et al. demonstrated that shedding of FLT3L and release from the mem-
brane are metalloprotease dependent and that this effect in fibroblasts is dependent on 
the TNFα-converting enzyme (TACE) [97]. Whilst we can only speculate, it is possible that 
blocking Cx43-mediated ATP release may blunt the activity of a protein(s) required for 
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FLT3 membrane shedding and, thus in the absence of FLT3L release, FLT3L levels in the 
supernatant are significantly less in TGFβ1+danegaptide-treated cells as compared to 
TGFβ1-treated controls. Interestingly, whilst danegaptide did not appear to reverse the 
TGFβ1-induced increase in the FLT3L cell lysate, it did have an effect on the secreted form 
of the protein. 
The soluble Receptor for Advanced Glycation Endproducts (RAGE) is a potential bi-
omarker of inflammation and oxidative stress [98]. It acts as a decoy receptor that prevents 
advanced glycation end products binding to membrane-bound RAGE and RAGE-related 
detrimental effects. In the current study, we observed a 70% increase in the secretion of 
sRAGE with TGFβ1, an effect restored to control by danegaptide. sRAGE is functional and 
able to induce an effect when secreted. The potential of danegaptide to significantly ne-
gate this secretion is of clear therapeutic interest. Interestingly, however, we did not ob-
serve an increase in the RAGE lysate at 48 h with TGFβ1 ± danegaptide. Whilst these ex-
periments have been performed in human primary proximal tubule cells, the limitations 
of our model may have cell-, time- and concentration-dependent effects. Consequently, 
whilst a better understanding of the mechanism of action of danegaptide is needed, find-
ings from this study provide important initial evidence of the benefits of using 
danegaptide to negate TGFβ1-induced changes in markers of inflammation and tubular 
injury via blockade of hemichannel-mediated ATP release. We concede that our in vitro 
data provide a minimalistic model of the multifactorial events that give rise to tubulointer-
stitial fibrosis, and recommend caution in translating these novel findings to the in vivo 
situation, especially where studies on other species and models of injury have demon-
strated variable effects [41,44,46–49]. Further studies are now required to determine the 
selectivity of these hemichannels and the capability of the drug in preclinical models of 
chronic damage, ahead of testing efficacy in human clinical trials. 
4. Materials and Methods 
4.1. Materials 
Clonal human kidney 2 (HK2) epithelial cells and primary human proximal tubule 
epithelial cells (hPTECs) were purchased from the American Type Culture Collection 
(ATCC) (LGC Standards). Tissue culture supplies were purchased from Invitrogen (Pais-
ley, UK). The Immobilon-FL PVDF membrane was from Millipore (Watford, UK), and 
Odyssey blocking buffer and secondary fluorescent antibodies were purchased from LI-
COR (Cambridge, UK). Antibodies for E-cadherin, N-cadherin, ILK1, MMP-3, β-catenin, 
vimentin and ZO-1 were obtained from Cell Signalling Technologies (Hertfordshire, UK), 
whilst claudin-2, laminin, collagen I and collagen IV antibodies were obtained from 
ABCAM (Cambridge, UK). Fibronectin antibody was purchased from Santa Cruz (Santa 
Cruz, CA, USA). 
Recombinant hTGFβ1 was obtained from Sigma (Poole, UK), as were all other gen-
eral chemicals. Danegaptide was provided by Zealand Pharmaceuticals. ATP biosensors 
were from Sarissa Biomedical Ltd. (Coventry, UK) and fluorodishes from WPI (Hertford-
shire, UK). Transwell filters were purchased from Corning (Nottinghamshire, UK). The 
Proteome Profiler Human Cytokine Array Kit was from R&D Systems (Oxfordshire, UK). 
4.2. Tissue Culture 
Primary human proximal tubule epithelial cells (hPTECs) were maintained in a renal 
epithelial cell basal medium from the ATCC, supplemented with 0.5% fetal calf serum 
(FCS wt/vol, triiodothyronine (10 nM), rhEGF (10 ng/mL), hydrocortisone hemisuccinate 
(100 ng/mL), rhInsulin (5 μg/mL), epinephrine (1 μM), transferrin (5 μg/mL) and L-alanyl-
L-glutamine (2.4 mM), in a humidified atmosphere at 37 °C with 5% CO2. Cells were sub-
jected to overnight serum starvation prior to treatment. Human kidney 2 (HK2) cells (pas-
sages 18–30) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)/Hams F12 
medium, supplemented with 10% FCS wt/vol, glutamine (2 mmol/L) and epithelial 
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growth factor (EGF) (5 ng/mL), in a humidified atmosphere at 37 °C with 5% CO2. HK2 
cells were immortalised by the transduction of human papilloma virus 16 (HPV-16) E6/E7 
genes and were mycoplasma free. In all experiments, cells were seeded in low-glucose 
DMEM/F12 (5 mmol/L) for 48 h and then serum-starved overnight prior to treatment. 
4.3. MTT Assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
performed, as described previously, to assess the cytotoxic effects of danegaptide on cell 
proliferation [99]. HK2 cells were seeded in 96-well plates and cultured in low-glucose 
DMEM/F12 (5 mM) for 48 h, prior to overnight serum starvation, and then subsequently 
stimulated for 48 h with TGFβ1 (10 ng/mL) ± danegaptide (50–1000 nM). Colourimetric 
measurement of formazan production corresponded to the number of viable cells. 
4.4. Lactate Dehydrogenase Assay 
The release of lactate dehydrogenase (LDH) into media as a result of plasma mem-
brane damage is commonly used to evaluate cell death or cytotoxicity. HK2 cells were 
seeded in 96-well plates and cultured in low-glucose DMEM/F12 (5 mM) for 48 h prior to 
overnight serum starvation. Cells were then stimulated for 48 h with TGFβ1 (10 ng/mL) ± 
danegaptide (50–1000 nM). The LDH cytotoxicity assay kit II (Abcam) was used to quan-
tify LDH according to the manufacturer’s instructions. 
4.5. Crystal Violet Assay 
This simple assay is used to measure the relative density of adhered cells to multi-well 
dishes. Crystal violet stains DNA and can be quantified colourimetrically after solubilisa-
tion. HK2 cells were seeded in 12-well plates and cultured in low-glucose DMEM/F12 (5 
mM) for 48 h, prior to overnight serum starvation, and then subsequently stimulated for 48 
h with TGFβ1 (10 ng/mL) ± danegaptide (50–1000 nM). The assay has been described previ-
ously [99]. Briefly, cells were fixed using paraformaldehyde for 10 min, washed with phos-
phate buffered saline (PBS) and incubated for 10 min at room temperature (RT) in a 0.1% 
crystal violet solution. After several more washes, the stain was solubilised using 1% SDS, 
and absorbance was measured by a plate reader. 
4.6. Western Blotting 
Preparation of cytosolic protein from HK2 cells and hPTECs, their separation by SDS-
gel electrophoresis and transfer onto Immobilon-FL PVDF membranes have been de-
scribed previously [12]. Membranes were blocked using Odyssey blocking buffer (LI-
COR) and then probed overnight with antibodies against E-cadherin (1:1000), N-cadherin 
(1:1000), claudin-2 (1:500), ZO-1 (1:1000), collagen I (1:1000), collagen IV (1:2000), fibron-
ectin (1:2000), laminin (1:500), ILK1 (1:500), β-catenin (1:2000), vimentin (1:500) and MMP3 
(1:500). Bands were visualised using OdysseyFC and semi-quantified using ImageStudio 
(v5.2, LI-COR, Lincoln, NE, USA). 
4.7. Transepithelial Resistance 
HK2 cells were seeded (6 × 104 cells/mL) onto Transwell filters (12 mm diameter, pore 
size 0.4 μM; Corning, NY, USA) and cultured in low-glucose DMEM/F12 (5 mM) for 48 h, 
serum-starved overnight and subsequently stimulated with TGFβ1 (10 ng/mL) ± danegaptide 
(100 nM) for 48 h. Transepithelial electrical resistance (TER) was measured using the EVOM 
apparatus (World Precision Instruments, Sarasota, FL, USA). A blank resistance measured 
from a well with medium alone was subtracted from each resistance reading. 
4.8. Dye Uptake Studies 
HK2 cells and hPTECs were seeded onto fluorodishes (22 mm diameter) and cultured 
in low-glucose DMEM/F12 (5 mmol/L) for 48 h. Following overnight serum starvation, 
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the cells were incubated with TGFβ1 (10 ng/mL) ± danegaptide (50–100 nM) for 48 h. For 
subsequent steps, a balanced salt solution (BSS, pH 7.0) comprising of NaCl (137 mM), 
KCl (5.4 mM), MgSO4 (0.8 mM), Na2HPO4 (0.3 mM), KH2PO4 (0.4 mM), NaHCO3 (4.2 mM), 
HEPES (10 mM) and glucose (5 mM) was used. To induce dye uptake, cells were exposed 
to Ca2+-free BSS (zero CaCl2 + EGTA (1 mM)) plus carboxyfluorescein (200 μM) for 10 min, 
followed by a 5 min period in Ca2+-containing BSS (1.3 mM) plus carboxyfluorescein (200 
μM). Dishes were subsequently washed with Ca2+-containing BSS (12 mL). Images were 
acquired with a Cool Snap HQ CCD camera (Roper Scientific, Gottingen, Germany) and 
Metamorph software (Universal Imaging Corp., Marlow, Bucks, UK). ImageJ was used to 
quantify dye uptake, where a region of interest (ROI) was drawn around each cell (approx. 
10–15 cells/dish) and the mean pixel intensity measured. A background fluorescence 
value was subtracted from each ROI. 
4.9. ATP Biosensing 
ATP biosensors (Sarissa Biomedical, Coventry, UK) were used in a simultaneous dual-
recording amperometric set-up, as described previously [12]. A null biosensor was used to 
account for non-specific electro-active artefacts and subtracted from the ATP trace. Glycerol 
(2 mM) was included in all recording solutions to enable ATP detection. HK2 cells were 
seeded on glass coverslips (10 mm diameter) in low-glucose DMEM/F12 (5 mmol/L) for 48 
h prior to overnight serum starvation. The cells were then incubated with TGFβ1 (10 ng/mL) 
± danegaptide (100 nM) for 48 h. The coverslips were transferred to a chamber containing 
Ca2+-containing BSS perfused at 6 mL/min (37 °C) and left for 10 min to acclimatise. ATP 
and null biosensors were bent and lowered so that the electrode lay parallel to the cellular 
monolayer. Once a stable baseline occurred, perfusion of Ca2+-free BSS stimulated hemi-
channel opening. After ATP release, Ca2+-containing BSS was used to close hemichannels, 
followed by a calibration solution of ATP (10 mM). Recordings were acquired at 4 Hz with 
a Micro CED (Mark2) interface using Spike (v8.03) software. 
4.10. Inflammation Antibody Array 
An inflammation antibody array (RnD Systems) assessed TGFβ1-induced regulation 
of 31 inflammatory markers. The array was performed by following the manufacturer’s 
instructions. Briefly, hPTECs were cultured in low-glucose DMEM/F12 (5 mM) for 48 h, 
prior to overnight serum starvation, and then subsequently stimulated for 48 h with 
TGFβ1 (10 ng/mL) ± danegaptide (100 nM). The cell lysates and supernatant were col-
lected and incubated overnight with pre-blocked membranes spotted in duplicate with 
capture antibodies. An 800 CW fluorescent streptavidin/biotinylated cocktail mixture was 
used to visualise expression protein/antibody complexes by using Odyssey FC and semi-
quantified using ImageStudio (v5.2, LI-COR). 
4.11. Quantitative Real-Time PCR 
RNA was extracted using an RNeasy mini kit (QIAGEN) and reverse-transcribed (Invi-
trogen). Real-time PCR (SYBR GreenER, Invitrogen) was performed using a StepOne Plus in-
strument (Applied Biosystems Inc, Foster City, CA, USA). cDNA expression was obtained by 
comparing to a standard curve of serially diluted cDNA. The following primers were used: 
p16 (forward: CTCGTGCTGATGCTACTGAGGA, reverse: GGTCGGCGCAGTT-
GGGCTCC), p21 (forward: AGGTGGACCTGGAGACTCTCAG, reverse: TCCTCTTGGA-
GAAGATCAGCCG), cyclin D1 (forward: TCTACACCGACAACTCCATCCG, reverse: 
TCTGGCATTTTGGAGAGGAAGTG), Klotho (forward: CCTCCTTTAC-
CTGAAAATCAGCC, reverse: CAGGTCGGTAAACTGAGACAGAG) and GAPDH (for-
ward: GTCTCCTCTGACTTCAACAGCG, reverse: ACCACCCTGTTGCTGTAGCCAA). 
Melt curve analysis confirmed primer specificity and checked for potential contamination. 
  




For all experiments, the low-glucose control (5 mM) was normalised to 100%, and all 
other conditions were compared to their respective controls. Statistical analysis was per-
formed using a one-way ANOVA test with Tukey’s multiple-comparison post-test. Data 
are expressed as the mean ± SEM, with n denoting the sample number. A p-value of ≤0.05 
signified statistical significance. 
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